James B. Yu, MD, MHS, FASTRO
he/him/his
Assistant Professor AdjunctDownloadHi-Res Photo
Cards
Appointments
Medical Oncology
Primary
Contact Info
Therapeutic Radiology
94 Woodland St.
Hartford, CT 06105
United States
About
Titles
Assistant Professor Adjunct
Biography
James Yu, MD, MHS, is a practicing radiation oncologist at Smilow Cancer Hospital at Saint Francis Hospital, Department of Radiation Oncology, in Hartford, CT.
He is a former Professor of Radiation Oncology at the Yale School of Medicine, and former Associate Chief Medical Officer of the Smilow Cancer Hospital and Care Centers. He was most recently the Executive Vice Chair of Columbia University Irving Medical Center Department of Radiation Oncology.
Dr. Yu specializes in treating genitourinary cancers such as kidney, bladder and prostate, central nervous system cancers and cases requiring stereotactic radiosurgery, and has presented and lectured internationally on these subjects. He also treats rectal, breast, and lung cancers at Saint Francis Hospital.
In his academic work, Dr. Yu conducts research on ways to use radiotherapy treatments to improve outcomes for cancer patients. “We need to push the field ever forward and not be satisfied with merely prolonging survival,” says Dr. Yu. “I think radiosurgery will play a role in this. As systemic therapies improve and our ability to control microscopically disseminated disease improves, noninvasive ablative therapies will become ever more important.”
As a former Yale Center for Clinical Investigation scholar and founding member of the Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center at Yale, Dr. Yu’s research centers on the comparative effectiveness of new radiation technologies and how these new technologies are adopted nationally.
Dr. Yu is currently the Deputy Editor-In-Chief of the journal Practical Radiation Oncology and is on the editorial boards of the Journal of Clinical Oncology - Clinical Cancer Informatics, JNCI, JNCI-Cancer Spectrum, European Urology - Oncology, Journal of Surgical Oncology, and Oncology (Williston Park), and former editorial board member of the Journal of Clinical Oncology.
He has published over 350 original manuscripts and co-edited the textbook Pocket Radiation Oncology and Principles of Clinical Cancer Research. He is the radiation oncology co-chair for the Southwest Oncology Group Genitourinary Cancers Committee, and a nationally recognized expert in patient reported outcomes.
Appointments
Medical Oncology
Assistant Professor AdjunctPrimary
Other Departments & Organizations
- Brain Tumor Center
- Center for Biomedical Data Science
- COPPER Center
- Gamma Knife Center
- Internal Medicine
- Medical Oncology
- Pituitary Program
- Prostate & Urologic Cancers Program
- Radiation Oncology
- Yale Cancer Center
- Yale Ventures
Education & Training
- MHS
- Yale University, Masters of Health Science (2014)
- Resident
- Yale New Haven Hospital (2009)
- Chief Resident
- Yale School of Medicine (2009)
- Intern
- California Pacific Medical Center, San Francisco, CA (2005)
- MD
- University of Michigan Medical School (2004)
- BS
- Yale University (1999)
Research
Overview
Medical Research Interests
Breast Neoplasms; Central Nervous System Neoplasms; Head and Neck Neoplasms; Radiotherapy, Intensity-Modulated; Urogenital Neoplasms
ORCID
0000-0002-3119-3226- View Lab Website
Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center at Yale
Research at a Glance
Yale Co-Authors
Frequent collaborators of James B. Yu's published research.
Publications Timeline
A big-picture view of James B. Yu's research output by year.
Research Interests
Research topics James B. Yu is interested in exploring.
Henry S. Park, MD, MPH
Cary Gross, MD
Veronica Chiang, MD, FAANS
Sanjay Aneja, MD
Kenneth B. Roberts, MD
Lynn D. Wilson, MD, MPH, FASTRO
408Publications
3,669Citations
Breast Neoplasms
Radiotherapy, Intensity-Modulated
Head and Neck Neoplasms
Publications
2024
Comparative Effectiveness of SBRT
Shen J, Sritharan D, Yu J, Aneja S. Comparative Effectiveness of SBRT. 2024, 455-467. DOI: 10.1007/978-3-031-67743-4_33.Peer-Reviewed Original ResearchConceptsStereotactic body radiation therapyEffect of stereotactic body radiation therapyAlternative to other treatment modalitiesStereotactic body radiation therapy treatmentLong-term follow-up of patientsFollow-up of patientsLong-term follow-upTreatment of brainOligometastatic diseaseRadiation therapyTreatment of cancerRetrospective seriesTreatment modalitiesRenal cancerCost-effectiveness studiesDatabase analysisCancerTreatmentProstateTherapyTestosterone Recovery and Associated Impact on Patient-Reported Health-Related Quality of Life (HRQoL) after Treatment with 6 Months of GnRH Agonist with or without Abiraterone Acetate plus Prednisone (AAP) and Apalutamide (Apa) in the FORMULA-509 Trial
Moningi S, Nguyen P, Rathkopf D, Zurita-Saavedra A, Spratt D, Dess R, Liauw S, Szmulewitz R, Einstein D, Bubley G, Yu J, An Y, Wong A, Feng F, Mckay R, Rose B, Shin K, Taplin M, Kollmeier M, Hoffman K. Testosterone Recovery and Associated Impact on Patient-Reported Health-Related Quality of Life (HRQoL) after Treatment with 6 Months of GnRH Agonist with or without Abiraterone Acetate plus Prednisone (AAP) and Apalutamide (Apa) in the FORMULA-509 Trial. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e563-e564. DOI: 10.1016/j.ijrobp.2024.07.1247.Peer-Reviewed Original ResearchConceptsMonths of GnRH agonistTestosterone recoveryGnRH agonistAssociated with lackClinically meaningful changeBaseline testosteroneAssociated with testosterone recoveryMedian follow-upEvaluated prior to treatmentTreatment groupsTrial randomized patientsHormonal functionPatient-reported health-related quality of lifeLog-rank testCompletion of treatmentMultivariate logistic regressionWilcoxon rank-sumPatient-reported HRQoL.Salvage radiationGleason scoreAbiraterone acetateHigher PSARecovery 1 yearRandomized patientsHealth-related quality of lifeLong-Term Patient-Reported Health-Related Quality of Life in the Randomized FORMULA-509 Trial of Salvage Radiotherapy and 6 Months of GnRH Agonist with Either Bicalutamide or Abiraterone Acetate Plus Prednisone and Apalutamide after Radical Prostatectomy
Hoffman K, Nguyen P, Rathkopf D, Zurita-Saavedra A, Spratt D, Dess R, Liauw S, Szmulewitz R, Einstein D, Bubley G, Yu J, An Y, Wong A, Feng F, Mckay R, Rose B, Lee K, Kibel A, Taplin M, Kollmeier M. Long-Term Patient-Reported Health-Related Quality of Life in the Randomized FORMULA-509 Trial of Salvage Radiotherapy and 6 Months of GnRH Agonist with Either Bicalutamide or Abiraterone Acetate Plus Prednisone and Apalutamide after Radical Prostatectomy. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: s54. DOI: 10.1016/j.ijrobp.2024.07.088.Peer-Reviewed Original ResearchConceptsAbiraterone acetate plus prednisoneMonths of GnRH agonistAcetate plus prednisonePatient-reported health-related quality of lifeEPIC-26Hormonal functionHealth-related quality of lifeGnRH agonistTreatment armsTreatment to 1 yearQuality of lifeMental statusMetastasis-free survivalBaseline to endCompletion of treatmentSalvage radiationSalvage radiotherapyOncological outcomesRadical prostatectomyClinically meaningful differencesSaint Louis University Mental Status ExamNear baselineClinically meaningful declineT-scoreHormonal domainsCancer care and the coconut tree: all in which it lives, and has come before
Yu J. Cancer care and the coconut tree: all in which it lives, and has come before. JNCI Cancer Spectrum 2024, 8: pkae083. PMID: 39428118, PMCID: PMC11491160, DOI: 10.1093/jncics/pkae083.Peer-Reviewed Original ResearchReply to O. Saifi et al
Yu J, DeStephano D, Horowitz D, Gross C, Cheng S. Reply to O. Saifi et al. Journal Of Clinical Oncology 2024, 42: 3763-3764. PMID: 39079081, DOI: 10.1200/jco-24-01228.Peer-Reviewed Original ResearchThe IDH paradox: Meta-analysis of alkylating chemotherapy in IDH-wild type and -mutant lower grade gliomas
Kinslow C, Roy S, Iwamoto F, Brown P, DeStephano D, Canoll P, Qureshi S, Gallito M, Sisti M, Bruce J, Horowitz D, Kachnic L, Neugut A, Yu J, Mehta M, Cheng S, Wang T. The IDH paradox: Meta-analysis of alkylating chemotherapy in IDH-wild type and -mutant lower grade gliomas. Neuro-Oncology 2024, 26: 1839-1849. PMID: 38943513, PMCID: PMC11449043, DOI: 10.1093/neuonc/noae102.Peer-Reviewed Original ResearchAltmetricConceptsProgression-free survivalIDH-mutant gliomasLow grade gliomasOverall survivalIDH-wtAlkylating chemotherapyGrade gliomasChemotherapy improves overall survivalMeta-analysis of randomized clinical trialsEffects of alkylating chemotherapyCompared to radiotherapyIDH-mutant tumorsWorld Health OrganizationIDH-wt glioblastomaIDH-wt gliomasMeta-analysisDiagnosis of glioblastomaIDH-wt tumorsIDH-wild typeRandomized clinical trialsRandom-effects modelMagnitude of benefitGlioblastoma trialsAnaplastic morphologyOS benefitUpdated Analysis of Comparative Toxicity of Proton and Photon Radiation for Prostate Cancer
Yu J, DeStephano D, Jeffers B, Horowitz D, Soulos P, Gross C, Cheng S. Updated Analysis of Comparative Toxicity of Proton and Photon Radiation for Prostate Cancer. Journal Of Clinical Oncology 2024, 42: 1943-1952. PMID: 38507655, DOI: 10.1200/jco.23.01604.Peer-Reviewed Original ResearchCitationsAltmetricConceptsIntensity-modulated radiation therapyProton beam therapyGU toxicityProstate cancerGI toxicityBenefits of proton beam therapyIntensity-modulated radiation therapy patientsPBT patientsLocalized prostate cancerTreatment-related toxicityComparison of GIStatistically significant differenceRadiation therapyBeam therapySEER-MedicareToxicity of protonProcedure codesComparative effectiveness studiesObservational studyPatientsSignificant differenceCancerMonthsComparing GIProstatePatient-reported health-related quality of life (HRQoL) in the randomized FORMULA-509 trial of salvage radiotherapy and 6 months of GnRH agonist with either bicalutamide or abiraterone acetate plus prednisone (AAP) and apalutamide (Apa) after radical prostatectomy (RP).
Hoffman K, Nguyen P, Rathkopf D, Zurita A, Spratt D, Dess R, Liauw S, Szmulewitz R, Einstein D, Bubley G, Yu J, An Y, Wong A, Feng F, McKay R, Rose B, Shin K, Kibel A, Taplin M, Kollmeier M. Patient-reported health-related quality of life (HRQoL) in the randomized FORMULA-509 trial of salvage radiotherapy and 6 months of GnRH agonist with either bicalutamide or abiraterone acetate plus prednisone (AAP) and apalutamide (Apa) after radical prostatectomy (RP). Journal Of Clinical Oncology 2024, 42: 260-260. DOI: 10.1200/jco.2024.42.4_suppl.260.Peer-Reviewed Original ResearchAltmetricConceptsAbiraterone acetate plus prednisoneSaint Louis University Mental Status ExamMonths of GnRH agonistPatient-reported health-related quality of lifeEPIC-26Radical prostatectomyHealth-related quality of lifeGnRH agonistTreatment armsHormonal functionPROMIS FatigueTreatment to 1 yearQuality of lifeAcetate plus prednisoneMental statusMetastasis-free survivalBaseline to endMental status examStandardized T scoresMild neurocognitive disorderCompletion of treatmentSalvage radiationSalvage radiotherapyOncological outcomesClinically meaningful differencesIntensification of ADT with enzalutamide in high-risk patients with biochemical relapse following radical prostatectomy undergoing salvage radiation: Initial results from RTOG 3506 (STEEL).
Posadas E, Gay H, Rodgers J, Morgan T, Xiao Y, Yu J, Michalski J, Bouchard M, Desai N, Funk R, Boike T, Jurgens D, Wong A, Shen X, Miyawaki L, Bland C, Hairston J, Sandler H, Pugh S, Feng F. Intensification of ADT with enzalutamide in high-risk patients with biochemical relapse following radical prostatectomy undergoing salvage radiation: Initial results from RTOG 3506 (STEEL). Journal Of Clinical Oncology 2024, 42: 131-131. DOI: 10.1200/jco.2024.42.4_suppl.131.Peer-Reviewed Original ResearchCitationsConceptsAndrogen deprivation therapyProgression free survivalSalvage radiotherapyHigh-risk featuresBiochemical relapseHigh-risk patientsRadical prostatectomyLHRH analogsDecreased lymphocytesAndrogen receptorMonths of androgen deprivation therapyGrade 3 adverse eventsProgression free survival benefitStandard androgen deprivation therapyMedian follow-up timeGrade 4 AEsPara-aortic radiotherapyProstate cancer patientsEnzalutamide armGleason 9Salvage radiationDeprivation therapyNodal involvementFree survivalRT boostBuilding on the past and creating a brave future: a message from the incoming editor in chief
Yu J. Building on the past and creating a brave future: a message from the incoming editor in chief. JNCI Cancer Spectrum 2024, 8: pkad096. PMID: 38185809, PMCID: PMC10868384, DOI: 10.1093/jncics/pkad096.Peer-Reviewed Original ResearchCitationsAltmetric
Academic Achievements & Community Involvement
honor Fellow
National AwardAmerican Society for Radiation OncologyDetails07/17/2023United Stateshonor Cancer Prevention and Control Research Prize
Yale School of Medicine AwardYale Cancer CenterDetails12/31/2017United Stateshonor Population Research Prize
Yale School of Medicine AwardYale Cancer CenterDetails11/22/2013United Stateshonor Seattle Prostate Brachytherapy Fellow
National AwardAmerican Brachytherapy SocietyDetails01/01/2009United Stateshonor Roentgen Resident Research Award
National AwardRSNADetails01/01/2008United States
News & Links
News
- July 17, 2024Source: Cancer Network
AI Use May Improve Treatment Outcomes in Prostate Cancer
- September 02, 2021
Smilow Cancer Hospital Patient and Family Forum
- June 05, 2019Source: OncLive
[VIDEO] Dr. Yu on the Drawbacks of Radiation Therapy in Prostate Cancer
- January 30, 2019Source: SpaceOAR Hydrogel
Meet Henry, a Patient who Prioritized His Health and Quality of Life When Facing Radiation Therapy for Prostate Cancer
Related Links
Get In Touch
Contacts
Email
Mailing Address
Therapeutic Radiology
94 Woodland St.
Hartford, CT 06105
United States
Locations
Smilow Cancer Hospital at Saint Francis
Academic Office
114 Woodland Street, Ste HRT 138
Hartford, CT 06105
Appointments
860.714.4568